Bioresponsive engineered nanoparticles for immunomodulation.

BMC Med · 2025 · PMC12574298 · PMID 41162977

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the OS benefit did not reach statistical significance in the entire cohort, a predefined subgroup analysis revealed a significant OS advantage in patients who had received concurrent chemoradiotherapy prior to vaccination ( NCT00409188 ) [ 358 , 359 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.